PCI Pharma Services Announces $1 Billion Investment in US Manufacturing Expansion
核心洞察
PCI Pharma Services announced infrastructure investments exceeding $1 billion to expand sterile fill-finish and drug-device combination capabilities across US operations.
The company is investing $100 million in a high-speed isolator filling line at its San Diego campus, scheduled to be operational in the first half of 2028.
New facilities will significantly increase capacity, including 250 million autoinjector units per year and production capabilities for 33 million vials annually.
PCI Pharma Services, a world-leading contract development and manufacturing organization (CDMO), announced a series of major infrastructure investments exceeding $1 billion to substantially expand its sterile fill-finish and advanced drug delivery capabilities across US and European operations. The expansion comes as pharmaceutical manufacturers increasingly prioritize US supply chain resilience for drug product development and manufacturing.
Major San Diego Campus Investment
At the center of PCI's investment strategy is a $100 million project at its San Diego campus, featuring a high-speed isolator filling line for ready-to-use (RTU) prefilled syringes and cartridges. The new line, scheduled to be operational in the first half of 2028, will more than double the site's existing syringe and cartridge filling capacity.
The San Diego facility will become PCI's second isolator fill-finish line at the campus, which currently supports and manufactures over 45 FDA-approved products. The campus hosts large-scale aseptic filling for prefilled syringes and cartridges, alongside specialized capabilities in oligonucleotides, peptides (搜索), complex formulations and lyophilization for injectables including nanoparticles (搜索), mRNA (搜索), monoclonal antibodies (搜索), proteins (搜索), and highly potent products.
Bedford Facility Enhancements
PCI's Bedford, New Hampshire campus is commissioning a GMP-ready bespoke isolator vial and lyophilization line that will commence full-scale production this month. The facility will be capable of producing batch sizes of up to 300,000 vials at 400 units per minute, for an annual total of 33 million units, representing one of the most robust, state-of-the-art setups of its kind in the US.
The Bedford campus will also commission a customer-dedicated high-potent sterile fill-finish line slated to be one of a kind in the US. Both San Diego and Bedford facilities have invested in cutting-edge automated visual inspection (AVI) systems for sterile fill-finish applications.
Drug-Device Combination Capabilities
In partnership with leading device manufacturers, PCI has committed to numerous buildouts of autoinjector and drug-device combination assembly infrastructure at its campuses in Philadelphia, PA and Rockford, IL. The upgrades, coming online via a phased approach over the next six months, will significantly increase both capacity and scale.
In 2027, PCI will add a third autoinjector line to its existing lineup, bringing its US autoinjector and device assembly capacity to more than 250 million units per year. The autoinjector lines feature multi-device tooling technology and flexible change parts, providing comprehensive high-speed assembly, while a dedicated prefilled syringe (PFS) safety device line adds labeling and secondary packaging options.
Packaging and Development Centers
Philadelphia and Rockford serve as PCI's US Packaging Centers of Excellence, offering capacity for oral solid dose and injectable products, as well as substantial cold chain storage. The GMP-compliant facilities can be rapidly mobilized to support programs at clinical or commercial scale, with available capacity across the two sites including annual accommodation for 40 million blister units, 70 million bottles, and 75 million vials.
PCI is also investing in dedicated Development Centers of Excellence (CoE) in Bedford, NH and León, Spain. The CoEs will feature development capabilities spanning lyophilization, formulation, analytical support, drug-device combination assets, long-acting injectables and ophthalmic products. They will handle both highly potent and non-potent small molecule and biologic modalities in vial, prefilled syringe and cartridge presentations. The Bedford Development CoE is expected to be operational this May, with León following in June.
Industry Impact and Leadership Perspective
"The pharmaceutical industry is at an inflection point, with manufacturers seeking trusted US-based partners to provide scale, expedience, and established quality and compliance track records to support the development and commercialization of next-generation treatments," said Salim Haffar, CEO of PCI Pharma Services. "Backed by over $1 billion in global infrastructure investment and decades of operational expertise, PCI's multi-year journey to bolster its domestic manufacturing footprint allows us to meet growing customer demand for innovative drug product and drug delivery solutions, toward the evergreen goal of delivering life-changing therapies to patients."
PCI currently operates 38 sites across seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain and Australia), employing over 7,500 people. The company brings proven experience from more than 90 successful product launches each year and over five decades in the healthcare services business, providing integrated end-to-end drug development, manufacturing and packaging capabilities from clinical stages through commercial launch.